Esperion Therapeutis.Inc. buy StockNews.com
Start price
17.08.25
/
50%
€1.70
Target price
17.08.26
-
Performance (%)
99.47%
Price
12.12.25
€3.28
Summary
This prediction is currently active. With a performance of 99.47% the BUY prediction by StockNews_com is a big success. This prediction currently runs until 17.08.26. The prediction end date can be changed by StockNews_com at any time. StockNews_com has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Esperion Therapeutis.Inc. | 2.657% | 2.657% |
| iShares Core DAX® | 0.734% | -0.964% |
| iShares Nasdaq 100 | -2.686% | -2.409% |
| iShares Nikkei 225® | -2.261% | -4.038% |
| iShares S&P 500 | -1.346% | -1.510% |
Comments by StockNews_com for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Esperion Therapeutics, Inc. (NASDAQ: ESPR) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Ratings data for ESPR provided by MarketBeat
Stopped prediction by StockNews_com for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
Start price
Target price
Perf. (%)
€1.93
26.10.24
26.10.24
-
26.10.25
26.10.25
18.51%
27.10.25
27.10.25
Esperion Therapeutis.Inc.
Start price
Target price
Perf. (%)
€1.97
05.10.24
05.10.24
-
05.10.25
05.10.25
41.81%
06.10.25
06.10.25